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Abstract
Introduction
Deployment of rotavirus vaccines has contributed to significant declines in diarrheal morbid-
ity and mortality globally. Unfortunately, vaccine performance in low-middle income coun-
tries (LMICs) is generally lower than in developed countries. The cause for this has been
associated with several host and maternal factors including poor water sanitation and
hygiene (WASH) status, which are predominant in LMICs. More recently, environmental
enteric dysfunction (EED) has specifically been hypothesized to contribute to poor vaccine
uptake and response. The aim of this study was to examine the association between sero-
logical biomarkers of EED and seroconversion to rotavirus vaccine in Zambian infants.
Methods
This was a retrospective cohort study of 142 infants who had been fully immunized with
Rotarix™, and had known seroconversion status. Seroconversion was defined as 4-fold or
more increase in rotavirus-specific IgA titres between pre-vaccination and one month post-
dose two vaccination. We performed ELISA assays to assess soluble CD14 (sCD14), Endo-
toxin Core IgG Antibodies (EndoCAb), intestinal fatty acid binding protein (i-FABP) and
Zonulin according to the manufacturers protocols. Generalised linear model with family-
poisson, link-log and robust standard error was used to estimate the independent effects of
biomarkers on seroconversion adjusting for important cofounders.
Results
The median concentration of Zonulin, Soluble CD14, EndoCaB, and IFABP were 209.3
(IQR = 39.7, 395.1), 21.5 (IQR = 21.5, 21.5), 0.3 (IQR = 0.3, 0.3), and 107.7 (IQR = 6.4,
1141.4) respectively. In multivariable analyses adjusting for the independent effect of other
biomarkers and confounders (i.e. age of child at vaccination, breast-milk anti-rotavirus IgA,
PLOS ONE | https://doi.org/10.1371/journal.pone.0187761 December 27, 2017 1 / 11
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Mwape I, Bosomprah S, Mwaba J, Mwila-
Kazimbaya K, Laban NM, Chisenga CC, et al.
(2017) Immunogenicity of rotavirus vaccine
(RotarixTM) in infants with environmental enteric
dysfunction. PLoS ONE 12(12): e0187761. https://
doi.org/10.1371/journal.pone.0187761
Editor: Miren Iturriza-Go´mara, University of
Liverpool, UNITED KINGDOM
Received: March 30, 2017
Accepted: October 25, 2017
Published: December 27, 2017
Copyright: © 2017 Mwape et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The data underlying
this study are restricted by the CIDRZ Ethics and
Compliance Committee. To request data access,
one must write to the Committee chair/Chief
Scientific Officer, Dr. Roma Chilengi, (Roma.
Chilengi@cidrz.org) or the Secretary to the
Committee/Head of Research Operations, Ms.
Hope Mwanyungwi (Hope.Mwanyungwi@cidrz.
org). The request for data must include contact
information, a research project title, and a
description of the analysis being proposed as well
as the format expected. The requested data should
infant serum anti-rotavirus IgG, and IgA seropositivity at baseline), there was strong evi-
dence of about 24% increase in seroconversion due to doubling Zonulin concentration
(Adjusted risk ratio (aRR) = 1.24; 95% CI = 1.12 to1.37; p<0.0001). Similarly, we found
about 7% increase in seroconversion due to doubling IFABP concentration (aRR = 1.07;
95% CI = 1.02 to 1.13; p = 0.006).
Conclusion
We found that high levels of zonulin and IFABP played a role in seroconversion. It is plausi-
ble that increased gut permeability in EED allows greater uptake of the live virus within the
vaccine, but later consequences result in deleterious local structural distortions and malab-
sorption syndromes.
Introduction
Diarrhea is the second largest killer of children in the world and rotavirus is the most common
cause of severe diarrhea among children <5 years of age globally [1]. Rotavirus caused an esti-
mated 233,000 deaths of children in 2013 alone, with the majority of these deaths occurring in
low and middle-income countries (LMICs) [2]. Zambia records over 3,600 rotavirus-related
deaths per year among children under 5 years [3].
Many LMICs are adding oral rotavirus vaccines (RVs) to their national immunization
schedules to reduce the burden of rotavirus diarrhea [4]; however, RVs are proving to have
lower immunogenicity, efficacy, effectiveness, and duration of protection in LMIC children
[5]. For example, while in US children, RV effectiveness against hospitalization for rotavirus
diarrhea was 87% (95% CI, 71%, 94%), in sub-Saharan Africa, clinical trials of the pentavalent
(RV5) and monovalent (RV1) RVs showed efficacies were 39% (95% CI, 19%, 55%) and 61%
(95% CI, 44%, 73%), respectively [6–13].
Several factors such as micronutrient deficiency, co-administration with oral poliovirus
vaccines and maternal breast milk factors have been suggested as reasons for low immunoge-
nicity of oral vaccines in developing countries [14, 15]. However, there is little known on the
effect of intestinal mucosal integrity on seroconversion following administration of rotavirus
vaccine [16].
Environmental enteric dysfunction (EED) is a syndrome of mucosal and sub-mucosal
inflammation, reduced intestinal absorptive capacity and reduced barrier function, which is
widespread in both adults and children residing in low and middle-income countries (LMICs)
[17, 18]. Chronic inflammation due to EED has been associated with non-specific responses to
oral vaccine antigens and result in clearance of the vaccine before sufficient induction of adap-
tive immunity [19–21]. Studies that have investigated EED have demonstrated intestinal archi-
tectural alterations such as crypt hyperplasia, blunting of the villi, and lymphocytic infiltration
of the lamina propria [20, 22, 23]. Individuals with EED can often be asymptomatic of gastro-
intestinal diseases but may demonstrate underlying malabsorption and low grade inflamma-
tion that may potentially result in failure of oral vaccines [20, 24, 25].
Several biomarkers have been shown to be associated with, mucosal dysfunction of the
small intestine in children under 5 years of age from developing countries [26]. Zonulin physi-
ologically modulates tight junctions of enterocytes of the digestive tract [27]. This protein
binds to a specific receptor on the surface of intestinal epithelia cells that induces tight junction
Environmental enteric dysfunction and immunity
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disassembly and a subsequent increase in permeability of the intestinal epithelia [28]. Intestinal
fatty acid binding protein (I-FABP) is a glycoprotein specifically secreted in circulation due to
enterocyte damage [29]. Soluble CD14 (sCD14) is the glycoprotein expressed mainly on the
surfaces of monocytes or macrophages which acts as a co-receptor along with Toll like receptor
type 4 to which later binds lipopolysaccharides [30, 31]. Fourth, is Endotoxin Core IgG Anti-
bodies (EndoCab); enhanced levels of this marker in serum may reflect a systemic inflamma-
tory response [32].
We hypothesised that the levels of these intestinal inflammation biomarkers, measuring
EED, may have an influence on seroconversion in infants receiving rotavirus vaccines. The
objective of the study was to examine the association of Zonulin, I-FABP, sCD14 and EndoCab
serum levels prior to vaccination with seroconversion in infants receiving rotavirus vaccine
(Rotarix™ -GSK Biologicals, Belgium) in Lusaka, Zambia.
Methods
Study site and participants
In this study, serum samples collected from infants receiving rotavirus vaccination in a previ-
ously described study were used [5]. Briefly, the study was conducted at Kamwala clinic, a
peri-urban health facility in Lusaka under which a prospective cohort of 420 infants aged
between 6 to 12 weeks and receiving Rotarix™ vaccine was enrolled between April 2013 and
March 2014. Blood was drawn from infants at baseline, before receiving the first dose of
Rotarix™ and at one month post vaccine dose two at which seroconversion status was deter-
mined based on a four-fold or greater increase in rotavirus-specific IgA from baseline. Ethical
approval was obtained from the University of Zambia Biomedical Research Ethics Committee
as well as the Institutional Review Board of the University of North Carolina, at Chapel Hill
USA. The study is registered at Clinical Trials.gov with NCT# 01886833.
Baseline sera from infants with known seroconversion status were included and tested for
presence of EED biomarkers. Of 420 enrolled infants, 216 had known seroconversion status:
82 classified as non-seroconverters, and 134 as seroconverters. Screening for EED biomarkers
was done for all of the non-seroconverters and for 60 randomly selected seroconverters as
illustrated in Fig 1.
Post-hoc power calculation
With a seroconversion rate estimated at 60% in the general population [5], the study sample of
142 infants had 85% power to detect a reduction in seroconversion to 35% using a 2-sided
Pearson Chi-Squared Test at 5% level of significance.
Laboratory procedures
Measurement of serum IgA and IgG. Rotavirus-specific serum IgA and IgG were deter-
mined by an antibody capture ELISA assay as previously described [5]. Plates were coated with
rabbit hyperimmune serum to rhesus rotavirus (RRV) and incubated with diluted RV1 strain
or blotto (5% skim milk in phosphate-buffered saline [PBS]). Following incubaton, plates were
washed and serially diluted serum samples in diluent buffer (1% skim milk and 0.5% [v/v] of
10% polyoxyethylene ether W1 in PBS) were added to the wells together with biotin-conju-
gated goat antihuman IgA antibodies. This was followed by the second incubation stage and
washing afterwards. Extravidin was then added to all wells and incubated. After incubation,
reactions were developed with 3,30,5,50-tetramethylbenzidine) and stopped with 1N hydrogen
chloride. Optical density (OD) were read at 450 nm with an enzyme immunoassay reader.
Environmental enteric dysfunction and immunity
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Calculation of IgA titres in serum were as the reciprocal of the highest dilution that gave a
mean OD greater than the cut-off value (3 standard deviations above the mean OD of the neg-
ative control serum wells). RV-specific IgG in serum samples was tested and analysed in a sim-
ilar way as IgA the only difference was that 0.5% normal rabbit serum was added to the biotin-
conjugated goat antihuman IgG antibody solution.
Measurement of serological biomarkers of EED. Commercial enzyme linked immuno-
sorbent assays (ELISA) kits were used to measure levels of sCD14, EndoCAb, I-FABP (Hycult
Biotech, Uden, Netherlands) and Zonulin (Immundiagnostik AG, Bensheim Germany)
according to the manufacturer’s instructions with modifications on sample dilutions. Undi-
luted plasma samples were used for measurement of sCD14 whereas samples were diluted 1:20
for Zonulin, 1:50 for Endocab and 1:10 for IFABP. Optical density was measured at 450nm
(ELX808 BioTek) and concentrations were determined using assay standard curve.
Statistical analysis
The primary outcome of interest was seroconversion defined as 4-fold or more increase in
rotavirus-specific IgA titres between pre-vaccination and one month post-dose -2 vaccination.
Rotavirus-specific IgA titres below limit of detection were imputed with 1 [5] before assessing
the fold-increase. The exposures of interest were serological EED biomarkers of intestinal
Fig 1. Infant recruitment and sample selection flow chart.
https://doi.org/10.1371/journal.pone.0187761.g001
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damage (IFABP), permeability (Zonulin) and microbial products of translocation (soluble
CD14 and Endocab). We summarised the concentration of EED biomarkers using median
and interquartile range. We used Fisher’s exact test to examine association of seroconversion
with key infant and maternal factors. We used test for trend to assess dose-response relation-
ship between the serological biomarkers of EED and seroconversion. The test for trend was
performed by modelling the median concentration in each quartile of the biomarker concen-
tration on seroconversion using a logit model.
Since this was a cohort study design we elected to estimate risk ratio using poisson with
robust standard error. Therefore, Generalised linear model with family-poisson, link-log and
robust standard error was used to estimate the independent effects of biomarkers on serocon-
version adjusting for important cofounders. The biomarkers were modelled on log base 2 scale
so that the effect would be doubling of the level of the biomarker. Values of biomarker concen-
trations below the limit of detection were imputed with half the lowest concentration for that
biomarker before the log-transformation. The analysis was performed using Stata 15 (Statcorp,
College Station, Texas, USA).
Results
A total of 142 infant plasma samples were assessed for serological EED biomarkers. The
median concentration of Zonulin, Soluble CD14, EndoCaB, and IFABP were 209.3 (IQR =
39.7, 395.1), 21.5 (IQR = 21.5, 21.5), 0.3 (IQR = 0.3, 0.3), and 107.7 (IQR = 6.4, 1141.4) respec-
tively (Table 1).
In univariable analyses, there was strong evidence that high levels of Zonulin (test for trend
p<0.0001) and IFABP (test for trend p = 0.001) were associated with increased probability of
seroconversion, while there was no evidence at 5% level of significance that high levels of
sCD14 (p = 0.189) and EndoCab (p = 0.073) were associated with seroconversion (Table 1,
Table 2).
In multivariable analyses adjusting for the independent effect of other biomarkers and con-
founders (i.e. age of child at vaccination, breast-milk anti-rotavirus IgA, infant serum anti-
rotavirus IgG, and IgA seropositivity at baseline), there was strong evidence of about 24%
increased in seroconversion due to doubling Zonulin concentration (Adjusted risk ratio
(aRR) = 1.24; 95% CI = 1.12 to1.37; p<0.0001) (Table 2). Similarly, we found about 7% in-
crease in seroconversion due to doubling IFABP concentration (aRR = 1.07; 95% CI = 1.02 to
1.13; p = 0.006).
Discussion
We report findings of the influence of intestinal inflammation biomarkers on seroconversion
in infants receiving rotavirus vaccines. We found that high levels of Zonulin and IFABP were
strongly associated with vaccine seroconversion. We also found very low levels of EndoCAb
and sCD14, which were not associated with seroconversion.
Zonulin and IFABP biomarkers are indicators of the integrity of the “Gate” (intestinal bar-
rier). Increased serum concentration reflects “Openness of the gate” and thus increased leaking
from the intestinal lumen into lamina propria. We think this implied easy vaccine uptake and
thus resulted into “better seroconversion”. Zonulin, as a tight junction modulator protein, is
secreted due to antigen binding to receptor on intestinal epithelial cell surface, which later
binds to EGF receptor (EGFR) via proteinase-activated receptor 2 (PAR2) [33]. Activation of
the two receptors initiates the cascade reaction resulting in tight junction protein disengage-
ment, this then enhances intercellular intestinal permeability [33, 34].
Environmental enteric dysfunction and immunity
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Table 1. Seroconversion at post dose 2 by environmental enteric dysfunction status and key infant and maternal factors.
Biomarkers and Characteristics Number of Infants (% of total) No. (%) seroconverted 95% CI Fisher’s exact P-value
Zonulin titre—Quartiles (median titre)
Median (IQR) 209.3 (39.7, 395.1) <0.0001*
1 (3.8) 36 (25) 6 (17) (8, 33)
2 (120.1) 35 (25) 16 (46) (30, 62)
3 (272.9) 35 (25) 21 (60) (43, 75)
4 (507.3) 35 (25) 23 (66) (48, 80)
Soluble CD14 titre—Quartiles (median titre)
Median (IQR) 21.5 (21.5, 21.5) 0.189 *
1 (21.5) 130 (92) 63 (48) (40, 57)
2 (NIL) 2 NIL NIL
3 (NIL) 2 NIL NIL
4 (243) 11 (8) 3 (27) (8, 60)
EndoCaB titre—Quartiles (median titre)
Median (IQR) 0.3 (0.3, 0.3) 0.073 *
1 (0.3) 125 (89) 62 (50) (41, 58)
2 (NIL) 2 NIL NIL
3 (NIL) 2 NIL NIL
4 (13.3) 16 (11) 4 (25) (9, 52)
IFABP titre—Quartiles (median titre)
Median (IQR) 107.7 (6.4, 1141.4) 0.001 *
1 (6.4) 67 (47) 17 (25) (16, 37)
2 (15.6) 4 (3) 3 (75) (18, 98)
3 (534.3) 35 (25) 22 (63) (46, 77)
4 (2555.7) 35 (25) 24 (69) (51, 82)
Age of child at vaccination (Weeks)
Median (IQR) 6 (6, 7) 0.034
<7 91 (65) 49 (54) (43, 64)
7+ 50 (35) 17 (34) (22, 48)
Sex of child
Female 66 (47) 28 (42) (31, 55) 0.398
Male 75 (53) 38 (51) (39, 62)
Infant serum anti-rotavirus IgG titre—Quartiles (median titre)
Median (IQR) 5120 (2560, 10240) 0.322
1 (2560) 49 (35) 27 (55) (41, 69)
2 (5120) 32 (23) 15 (47) (30, 64)
3&4 (10240) 1 59 (42) 24 (41) (29, 54)
Seropositivity at baseline (IgA > = 1:40)
No 107 (76) 54 (50) (41, 60) 0.167
Yes 34 (24) 12 (35) (21, 53)
Age of mother (Years)
Median (IQR) 24 (22, 29) 0.590
16–19 18 (13) 7 (39) (19, 63)
20–24 56 (40) 28 (50) (37, 63)
25–29 33 (23) 13 (39) (24, 57)
30–39 34 (24) 18 (53) (36, 69)
Maternal HIV Status
(Continued )
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Elevated levels of zonulin in serum has been found to be associated with rotavirus infection
in infants in Poland [35]. Further, it has been demonstrated that Dendritic Cells (DC) open
the tight junctions between epithelial cells, send dendrites directly in the lumen for antigen
sampling [36–38], suggesting that increased permeablility evidenced by high levels of Zonulin
facilitates sending DC processes in lumen for antigen upatake. Also, antigen-nonspecific trans-
port occurs through transcellular or paracellular pathways when the tight junction becomes
more permeable or damaged by environmental factors. This increased uptake of antigens may
occur as a result of allergic enteropathy, and other environmental factors that activate inflam-
matory cascades [39–41].
On the other hand, intestinal fatty-acid binding protein (I-FABP) is expressed in epithelial
cells of the mucosal layer of the small intestine tissue [42]. When intestinal mucosal damage
occurs due to presence of microbes or dietary antigens, gut barrier integrity can be disrupted
leading to increased intestinal permeability [43]. This breach of intestinal barrier facilitates
increased uptake of microbial products as well as live vaccines. These mechasims were sup-
ported by our findings that high levels of Zonulin and IFABP was associated with seroconver-
sion. We think the high levels of Zonulin and IFABP implied early infant exposure to poor
sanitation and hygiene, and therefore exposure to pathogens causing intestinal inflammation.
Table 1. (Continued)
Biomarkers and Characteristics Number of Infants (% of total) No. (%) seroconverted 95% CI Fisher’s exact P-value
Negative 88 (62) 42 (48) (37, 58) 0.862
Positive 53 (38) 24 (45) (32, 59)
Breast-milk anti-rotavirus IgA—Quartiles (median titre)
Median (IQR) 160 (80, 320) 0.053
1 (80) 54 (40) 32 (59) (46, 72)
2 (160) 30 (22) 11 (37) (21, 55)
3 (320) 28 (21) 12 (43) (26, 62)
4 (640+) 24 (18) 7 (29) (14, 50)
Total 141 66 (47) (39, 55)
1 3rd and 4th Quartiles were combined because the frequencies were small
2 Over 90% of titres were below limit of detection and therefore 25th, 50th, 75th percentiles were the same as shown in the interquartile range (IQR)
* P-values were calculated using logit model where median titres were used to test for trend
https://doi.org/10.1371/journal.pone.0187761.t001
Table 2. Independent effects of markers of environmetal enteric dysfunction on seroconversion post dose 2 among rotavirus vaccinated infants
aged 6–11 weeks.
Biomarkers Crude RR (95%CI) P-value Adjusted RR (95%CI) 1 Adjusted P-value
Zonulin
Titre transformed to log base 2 1.26 (1.14, 1.40) <0.0001 1.24 (1.12, 1.37) <0.0001
Soluble CD14
Titre transformed to log base 2 0.91 (0.71, 1.16) 0.438 0.91 (0.73, 1.13) 0.380
EndoCaB
Titre transformed to log base 2 0.92 (0.79, 1.08) 0.307 0.98 (0.85, 1.14) 0.807
IFABP
Titre transformed to log base 2 1.11 (1.06, 1.17) <0.0001 1.07 (1.02, 1.13) 0.006
1 Estimates were adjusted for biomarkers (transformed on log base 2); and Age of child at vaccination (binary); Breast-milk anti-rotavirus IgA (transformed
on log base 2); Seropositivity at baseline (IgA > = 1:40) (binary); Infant serum anti-rotavirus IgG (transformed on log base 2)
https://doi.org/10.1371/journal.pone.0187761.t002
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The timing of the samples just before the first vaccine dose was appropriate as it reflects the
EED status of the internal milieu. We postulated that if the live oral vaccine is taken around
such a time, the increased translocation of luminal microbes and their products actually facili-
tated better vaccine uptake. This thinking is consistent with the known mechanism for natural
infections [17, 20, 21]. Our finding is consistent with that of a Bangladeshi study in which
IFABP had positive association with oral chorela vaccine [44].
However, soluble CD14 and Endocab are markers of responses to lipopolysaccharides
(LPS), a product of gram negative bacterial cell wall, which indicate “Gut leakage”. It has been
postulated that high levels of sCD14 in the plasma are reflective of LPS exposure [45]. The low
levels of soluble CD14 and Endocab found in our study may suggest that infants were less
exposed to intestinal bacterial infection.
We acknowledge some limitations in our study. First, stool biomarkers were not used to
asses EED [46]. Second, we did not assess the intestinal microbiota, which has been shown to
have an effect on vaccine responses among infants [47]. Third, there may be other unmeasured
confounders that could impact immune responses. Despite these limitations, we believe that
the findings are relevant to warrant future studies establishing the levels of Zonulin and IFABP
at which immune activation due to increased permeability does not lead to negative associa-
tion of vaccine seroconversion.
Conclusion
We found that high levels of zonulin and IFABP played a role in seroconversion. It is plausible
that increased gut permeability in EED allows greater uptake of the live virus within the vac-
cine, but later consequences result in deleterious local structural distortions and malabsorption
syndromes.
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